FEATURED NEWS

• HDA Traceability Seminar to Feature FDA Update, Discussions on DSCSA Milestones

  August 10, 2018

  As the summer winds down, HDA is hard at work planning our 2018 Traceability Seminar, which will take place three weeks earlier, on October 17–19 at the Renaissance Washington, DC Downtown Hotel (http://bit.ly/2MwTuhd). As the industry passes the halfway mark for Drug Supply Chain Security Act (DSCSA) implementation, our 2018 agenda leverages HDA and our members’ unique expertise to help fellow stakeholders answer critical questions while planning for the multiple milestones ahead.

• HDA Research Foundation Report Analyzes Reverse Distribution of Pharmaceutical Products

  August 6, 2018

  A new report published by the HDA Research Foundation entitled The Role of Reverse Distribution provides insights into the reverse distribution of pharmaceutical products. The Foundation estimates that this channel accounts for 3.5 to 4 percent of all pharmaceutical sales — more than 120 million product units — and exceeds $13 billion in product value.

• HDA Statement on FDA Work Group to Examine Prescription Drug Importation

  July 20, 2018

  Healthcare Distribution Alliance (HDA) President and CEO John M. Gray released the following statement on the Department of Health and Human Services’ (HHS) recent directive to establish a Food and Drug Administration (FDA) work group to examine prescription drug importation policies.

• HDA Statement on Senator McCaskill’s Opioid Report and the Role of Pharmaceutical Distributors in Addressing National Crisis

  July 12, 2018

  In response to a new report from Sen. Claire McCaskill (D-Mo.) regarding the role of distributors in addressing the country’s opioid abuse epidemic, Healthcare Distribution Alliance (HDA) President and CEO John M. Gray issued the following statement.

• Fact Check: Where 60 Minutes Got it Wrong on the Opioid Crisis

  July 12, 2018

  Over the last year, 60 Minutes, in partnership with The Washington Post, has presented several misleading, inaccurate accounts of pharmaceutical distributors’ role in the opioid crisis, including the subsequent enforcement of The Ensuring Patient Access and Effective Drug Enforcement Act. To understand the country’s opioid epidemic and the solutions needed to reduce diversion and misuse of prescription opioids, we need to separate fact from fiction.